Literature DB >> 1362183

Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles.

S J Harris1, A J Gearing, G T Layton, S E Adams, A J Kingsman.   

Abstract

The induction of CD4+ T-helper (Th) cell responses is likely to be an important requirement of vaccine candidates designed to prevent or moderate human immunodeficiency virus-1 (HIV-1) infection. We have investigated the ability of hybrid Ty virus-like particles carrying the V3 loop region of the HIV-1 IIIB envelope gp120 (V3:Ty-VLP) to elicit V3-specific proliferative responses. Significant proliferation in response to stimulation in vitro with homologous IIIB V3 peptide was observed following immunization of mice with V3:Ty-VLP either as an aluminium hydroxide precipitate or without adjuvant. Responses to MN V3 peptide were also observed in certain mouse haplotypes. To assess the effect of presenting the V3 loop in this particulate form, we compared the responses induced by V3:Ty-VLP with those obtained with two non-particulate immunogens, recombinant gp120 (rgp120) and V3 peptide conjugated to albumin. V3-specific responses to V3 peptide in vitro were reproducibly higher following immunization with V3:Ty-VLP than with either rgp120 or V3-albumin coagulate (V3-alb). The data indicate that immunization with the V3 loop as a hybrid Ty-VLP results in enhanced proliferative responses to V3 peptide and recognition of rgp120 in vitro. Some cross-reactivity of Th cells for V3 sequences from different isolates was also observed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362183      PMCID: PMC1421720     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1.

Authors:  K H Mills; P A Kitchin; B P Mahon; A L Barnard; S E Adams; S M Kingsman; A J Kingsman
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

Review 2.  Immunological adjuvants: a role for liposomes.

Authors:  G Gregoriadis
Journal:  Immunol Today       Date:  1990-03

3.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

4.  Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.

Authors:  J R Rusche; D L Lynn; M Robert-Guroff; A J Langlois; H K Lyerly; H Carson; K Krohn; A Ranki; R C Gallo; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 5.  The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses.

Authors:  J J Farrar; W R Benjamin; M L Hilfiker; M Howard; W L Farrar; J Fuller-Farrar
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

6.  Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.

Authors:  B Wahren; L Morfeldt-Månsson; G Biberfeld; L Moberg; A Sönnerborg; P Ljungman; A Werner; R Kurth; R Gallo; D Bolognesi
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

7.  Prevalence, incidence, and progression of human immunodeficiency virus infection in homosexual and bisexual men in hepatitis B vaccine trials, 1978-1988.

Authors:  N A Hessol; A R Lifson; P M O'Malley; L S Doll; H W Jaffe; G W Rutherford
Journal:  Am J Epidemiol       Date:  1989-12       Impact factor: 4.897

8.  Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.

Authors:  P A Broliden; B Mäkitalo; L Akerblom; J Rosen; K Broliden; G Utter; M Jondal; E Norrby; B Wahren
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

9.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

10.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  4 in total

1.  Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

Authors:  G T Layton; S J Harris; J Myhan; D West; F Gotch; M Hill-Perkins; J S Cole; N Meyers; S Woodrow; T J French; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

2.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.

Authors:  S Peifang; G L Pira; D Fenoglio; S Harris; M G Costa; V Venturino; V Dessì; G Layton; J Laman; J G Huisman
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

Review 4.  Efficacy of AIDS vaccine strategies in nonhuman primates.

Authors:  Klaus Uberla
Journal:  Med Microbiol Immunol       Date:  2005-04-21       Impact factor: 3.402

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.